Vaxil Announces Update on Non-Brokered Private Placement

Executive Summary

• Vaxil Bio Ltd. announced a revised non‑brokered private placement of up to 3,111,111 units at $0.1125 per unit, targeting gross proceeds of up to $350,000.
• Each unit consists of one common share and one warrant; the warrant allows purchase of an additional share at $0.15 for five years.
• The offering is expected to close around December 4 2025, subject to TSX Venture Exchange approval, with a four‑month hold period on the securities.

Key Details

• Units Offered: Up to 3,111,111 units (each = 1 common share + 1 share purchase warrant).
• Pricing: $0.1125 per unit; total gross proceeds targeted at up to $350,000.
• Warrant Terms: Holders may acquire one additional share at $0.15 per share for five years after closing.
• Use of Proceeds: General corporate purposes.
• Closing Timeline: Anticipated on or about December 4 2025, contingent upon TSX Venture Exchange approval and other customary conditions.
• Finder Compensation: Up to 8% cash commission of gross proceeds plus issuance of non‑transferable Finders’ Warrants equal to up to 8% of the aggregate number of units issued.
• Hold Period: Units, shares, warrants, and Finders’ Warrants subject to a four‑month and one‑day hold period from issuance per securities law requirements.

Notable Quotes

(No direct quotes were provided in the release.)